Market Cap 52.70B
Revenue (ttm) 50.43B
Net Income (ttm) -2.76B
EPS (ttm) N/A
PE Ratio 9.41
Forward PE 9.02
Profit Margin -5.48%
Debt to Equity Ratio 1.33
Volume 1,003,500
Avg Vol 880,272
Day's Range N/A - N/A
Shares Out 3.93B
Stochastic %K 96%
Beta 0.68
Analysts Strong Sell
Price Target $14.18

Company Profile

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equ...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 49 214 30 1
Address:
Kaiser-Wilhelm-Allee 1, Leverkusen, Germany
Quantumup
Quantumup May. 22 at 3:16 PM
Truist⬆️the PT on $ABCL to $12 (was $10), reiterated at Buy and said—Clinical Signal & Platform Promise: What VMS Data Could Mean for ABCL's Next Phase $ALPMY $BAYRY Truist added—We reiterate our ABCL Buy rating following Ph1 ABCL-635 data that shows 1) target engagement and 2) clean safety profile that could support a superior safety profile vs. competitors. We look to Ph2 data (3Q26) to confirm or exceed efficacy seen with Veozah/Lynkuet and see favorable risk-reward benefit leading into the data. We believe 635 showing pbo-adjusted reductions in VMS frequency of ~20-25% and severity of ~10-15% could lead to upside potential of 20-60%+ vs. 20-40% downside from negative data (preview w/ scenario analyses). We updated our model to include a VMS revenue build (vs. prior project fee), reflecting how we think investors will view the stock.
0 · Reply
sideload
sideload May. 21 at 3:47 PM
0 · Reply
11thestate
11thestate May. 21 at 1:53 PM
If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $BAYRY — how you can actually recover something, late claims are currently being accepted: https://11th.com/cases/bayer-investor-settlement
0 · Reply
HereForFunsies
HereForFunsies May. 20 at 7:18 PM
$BAYRY that's some nice volume today 👀 Sure wouldn't mind this to move back upward as we wait for a SCOTUS ruling. I'll trim in the mid 12s
0 · Reply
HboFam
HboFam May. 20 at 6:25 PM
$SLS @cb5000calls $AZN and $BAYRY have to be on the short list of possible Tambiciclib suitors.
0 · Reply
HboFam
HboFam May. 20 at 6:04 PM
$AZN $BAYRY Tambiciclib Suitors
0 · Reply
Arkasha
Arkasha May. 15 at 7:28 PM
$BAYRY I just don't understand how this is still surpressed
1 · Reply
Quantumup
Quantumup May. 12 at 12:43 PM
Stifel y'day⬆️ $ABCL's PT to $8 (was $7), reit'd Buy/said it now models ABCL635 peak U.S. sales of $1.4B and $800M in menopause-related VMS and oncology-related (specifically early-stage breast cancer) VMS. $ALPMY $BAYRY Here's what Stifel said in its note: https://x.com/Quantumup1/status/2054180048857424221?s=20
0 · Reply
HereForFunsies
HereForFunsies May. 12 at 11:47 AM
$BAYRY nice earnings beat, let's go!
0 · Reply
PickAlpha
PickAlpha May. 11 at 12:00 PM
6/6: BASF commissions Ludwigshafen “BioHub” fermentation plant to make biological crop-protection actives in-house; investment cited in high double‑digit € millions. $BASFY $BAYRY $CTVA $FMC $MOS
0 · Reply
Latest News on BAYRY
No data available.
Quantumup
Quantumup May. 22 at 3:16 PM
Truist⬆️the PT on $ABCL to $12 (was $10), reiterated at Buy and said—Clinical Signal & Platform Promise: What VMS Data Could Mean for ABCL's Next Phase $ALPMY $BAYRY Truist added—We reiterate our ABCL Buy rating following Ph1 ABCL-635 data that shows 1) target engagement and 2) clean safety profile that could support a superior safety profile vs. competitors. We look to Ph2 data (3Q26) to confirm or exceed efficacy seen with Veozah/Lynkuet and see favorable risk-reward benefit leading into the data. We believe 635 showing pbo-adjusted reductions in VMS frequency of ~20-25% and severity of ~10-15% could lead to upside potential of 20-60%+ vs. 20-40% downside from negative data (preview w/ scenario analyses). We updated our model to include a VMS revenue build (vs. prior project fee), reflecting how we think investors will view the stock.
0 · Reply
sideload
sideload May. 21 at 3:47 PM
0 · Reply
11thestate
11thestate May. 21 at 1:53 PM
If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $BAYRY — how you can actually recover something, late claims are currently being accepted: https://11th.com/cases/bayer-investor-settlement
0 · Reply
HereForFunsies
HereForFunsies May. 20 at 7:18 PM
$BAYRY that's some nice volume today 👀 Sure wouldn't mind this to move back upward as we wait for a SCOTUS ruling. I'll trim in the mid 12s
0 · Reply
HboFam
HboFam May. 20 at 6:25 PM
$SLS @cb5000calls $AZN and $BAYRY have to be on the short list of possible Tambiciclib suitors.
0 · Reply
HboFam
HboFam May. 20 at 6:04 PM
$AZN $BAYRY Tambiciclib Suitors
0 · Reply
Arkasha
Arkasha May. 15 at 7:28 PM
$BAYRY I just don't understand how this is still surpressed
1 · Reply
Quantumup
Quantumup May. 12 at 12:43 PM
Stifel y'day⬆️ $ABCL's PT to $8 (was $7), reit'd Buy/said it now models ABCL635 peak U.S. sales of $1.4B and $800M in menopause-related VMS and oncology-related (specifically early-stage breast cancer) VMS. $ALPMY $BAYRY Here's what Stifel said in its note: https://x.com/Quantumup1/status/2054180048857424221?s=20
0 · Reply
HereForFunsies
HereForFunsies May. 12 at 11:47 AM
$BAYRY nice earnings beat, let's go!
0 · Reply
PickAlpha
PickAlpha May. 11 at 12:00 PM
6/6: BASF commissions Ludwigshafen “BioHub” fermentation plant to make biological crop-protection actives in-house; investment cited in high double‑digit € millions. $BASFY $BAYRY $CTVA $FMC $MOS
0 · Reply
KilroyPicks
KilroyPicks May. 7 at 8:09 PM
$MIST - Top Strategic Acquires Continued Part 3 3. Bayer $BAYRY Bayer is currently refocusing its pharmaceutical division to counter the loss of revenue from Xarelto. Strategic Fit: Bayer has explicitly stated a focus on cardiovascular diseases and has been active in small-to-mid-cap M&A recently (e.g., the acquisition of Perfuse Therapeutics in May 2026). Synergy: CARDAMYST offers a "medtech-like" pharmaceutical solution (a self-administered spray) that fits Bayer’s history of specialized, high-margin cardiovascular products.
1 · Reply
HereForFunsies
HereForFunsies May. 7 at 11:25 AM
$BAYRY this thing is a yo-yo until we get clarity on litigation. One day back above 11 and the next below 🤦‍♂️
0 · Reply
sideload
sideload May. 6 at 11:36 PM
1 · Reply
OldHam
OldHam Apr. 30 at 10:11 PM
$BAYRY whats likelihood we get back to $30 levels seen in 2017? What would it take to get there?
1 · Reply
scottptts
scottptts Apr. 30 at 7:52 PM
$BAYRY Not sure what changed over the past couple of days
2 · Reply
HereForFunsies
HereForFunsies Apr. 30 at 2:49 PM
$BAYRY wow back into its long term pattern was most certainly not expected today lol
0 · Reply
11thestate
11thestate Apr. 30 at 2:32 PM
[FAQ] Everything you need to know about the $38 million $BAYRY Settlement Q: Am I actually eligible? A: If you bought $BAYRY shares between May 23, 2016, and July 6, 2020, you’re likely eligible. You don’t need to hold the stock still to claim; past losses count. Just click the link below to submit your claim through our secure portal. https://11th.com/cases/bayer-investor-settlement Q: How much will I actually get? A: The current estimated payout is $0.23 per share. The final amount depends on how many people file; if fewer people claim, the payout per share can actually increase for those who did! Q: When do payouts happen? A: Typically, within 4–9 months after the claim deadline. But the exact timing depends on the court and settlement administration. Q: I missed the deadline. Is it too late? A: Not necessarily. We are currently processing 'Late-but-Valid' claims. The court often accepts these as long as the fund hasn't been distributed yet.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 29 at 9:04 PM
$SLS Old AJAX buyout news - from yesterday, should give, even the most conservative of investors, great comfort, and conviction in accumulating SLS shares at $0.888B /$4.70. Ajax $2.3B purchase based on preclinical data, for heme disease - sets an absolute floor $15 , for 009 value. - 009 Newly Diagnosed Front Line AML-MR / Tp53 MOS was Not Reached in the PH2B AML-MR 1L Data published at ASH, was at least 9 months. - MOS in the Ongoing SLS009 Pivotal Randomize Expansion will be greater than the SOC - 9.7months AML-MR /3-6 month Tp53 MOS. SLS009 Related Toxicities: the Key to 009 Value, on Target Selectivity eliminates toxicity. $BAYRY
0 · Reply
TalkMarkets
TalkMarkets Apr. 27 at 11:30 AM
5 AgTech Investments That Are Actually Paying Off In 2026 $DE $ICL $AGCO $BAYRY https://talkmarkets.com/article/5-agtech-investments-that-are-actually-paying-off-in-2026-1777289414
0 · Reply
HereForFunsies
HereForFunsies Apr. 23 at 1:56 PM
$BAYRY Solicitor General being allowed to speak during SCOTUS hearing next week. MDL leadership denied. I think Bayer has some favor going into this finally. Here's to hoping it goes in Bayer's direction 🙏 not just for the investment, but for the sake of future farming and yield https://www.supremecourt.gov/docket/docketfiles/html/public/24-1068.html?utm_source=chatgpt.com
1 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 22 at 1:59 AM
$TAK IMT-009 + fruquintinib Ph1b in 3L+ MSS CRC: 5.3% ORR, 47.4% DCR, zero DLTs, only 5.3% Grade 3 events. "Silent partner" safety vs $AGEN botensilimab is the moat. TLS biomarker enrichment + Project Optimus dose-finding (240mg vs 800mg) are the required unlocks. $BAYRY #MSSCRC Read more: https://www.clinicaltrialsdaily.com/cd161-clec2d-checkpoint-inhibitor-colorectal-cancer/
2 · Reply
HereForFunsies
HereForFunsies Apr. 21 at 3:45 PM
$BAYRY dip before the SCOTUS rip?? 👀 Case starts next week. Here's to hoping it goes in our favor 🙌
0 · Reply